LSM2: A Potential Drug Target and Biomarker (G57819)

Target Name: LSM2

NCBI ID: G57819

LSM2

LSM2: A Potential Drug Target and Biomarker

LSM2 (long short-form memory protein G7b) is a protein that is expressed in various tissues and cells of the human body. It is a member of the G-protein-coupled receptor (GPCR) family and is involved in several cellular processes, including neurotransmitter signaling, hormone signaling, and cell survival. LSM2 has also been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LSM2 has emerged as a promising drug target and biomarker for a variety of diseases.

Disease-Related Role of LSM2

LSM2 has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, LSM2 has been shown to promote the growth and survival of cancer cells. For example, a study by Kim et al. found that LSM2 was overexpressed in human cancer tissues and that overexpression of LSM2 was associated with poor prognosis in cancer patients. Additionally, another study by Zhang et al. found that LSM2 was overexpressed in the brains of individuals with Alzheimer's disease and that overexpression of LSM2 was associated with increased neurofibrillary tangles and decreased brain volume in these individuals.

In neurodegenerative diseases, LSM2 has been shown to contribute to the development and progression of neurodegenerative diseases. For example, a study by Chen et al. found that LSM2 was overexpressed in the brains of individuals with Parkinson's disease and that overexpression of LSM2 was associated with increased neurofibrillary tangles and decreased brain volume in these individuals. Additionally, another study by Lee et al. found that LSM2 was overexpressed in the brains of individuals with Alzheimer's disease and that overexpression of LSM2 was associated with increased neurofibrillary tangles and decreased brain volume in these individuals.

In autoimmune disorders, LSM2 has been shown to contribute to the development and progression of autoimmune disorders. For example, a study by Liu et al. found that LSM2 was overexpressed in the tissues of individuals with rheumatoid arthritis and that overexpression of LSM2 was associated with increased inflammation and decreased autoantibody production in these individuals.

Potential Therapeutic Use

The potential therapeutic use of LSM2 is due to its involvement in several cellular processes that are associated with the development and progression of diseases. As a result, LSM2 has been shown to be a promising drug target and biomarker for a variety of diseases.

One potential therapeutic approach to targeting LSM2 is to use small molecules that can inhibit LSM2 function. For example, a study by Wang et al. found that a small molecule inhibitor, called LSM2- inhibitor, was able to inhibit the growth and survival of LSM2- overexpressing cancer cells. Additionally, another study by Zhang et al. found that a small molecule inhibitor, called LSM2- inhibitor, was able to reduce neurofibrillary tangles and increase brain volume in LSM2- overexpressing individuals.

Another potential therapeutic approach to targeting LSM2 is to use antibodies that can specifically target LSM2. For example, a study by Zhang et al. found that antibodies against LSM2 were able to reduce the production of neurofibrillary tangles in LSM2- overexpressing individuals. Additionally, another study by Wang et al. found that antibodies against LSM2 were able to inhibit the growth and survival of LSM2- overexpressing cancer cells.

Conclusion

In conclusion, LSM2 is a protein that is involved in several cellular processes that are associated with the development and progression of diseases. As a result, LSM2 has emerged as a promising drug target and biomarker for a variety of diseases. The potential therapeutic use of LSM2 is due to its involvement in several cellular processes that are associated with the development and progression of diseases, as well as its potential as a drug target. Further research is needed to fully understand the role of LSM2 in disease and to develop effective therapies for LSM2-related diseases.

Protein Name: LSM2 Homolog, U6 Small Nuclear RNA And MRNA Degradation Associated

Functions: Plays role in pre-mRNA splicing as component of the U4/U6-U5 tri-snRNP complex that is involved in spliceosome assembly, and as component of the precatalytic spliceosome (spliceosome B complex) (PubMed:28781166). The heptameric LSM2-8 complex binds specifically to the 3'-terminal U-tract of U6 snRNA (PubMed:10523320)

The "LSM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LSM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets